Abstract:Immune checkpoint blockade therapy targeting programmed death-1 (PD-1) or its major ligand pro-grammed death-ligand 1 (PD-L1) has achieved remarkable success in the treatment of several tumors, including colorectal cancer. However, the efficacy of PD-1/PD-L1 inhibitors is limited in some colorec-tal cancers within the immunosuppressive tumor microenvironment (such as when there is a lack of immune cell infiltration). Herein, anti-PD-L1 functionalized biomimetic polydopamine-modified gold nanostar nanoparticles (PDA/GNS@aPD-L1 NPs) were developed for synergistic anti-tumor treatment by combining PD-1/PD-L1 blockade with photothermal ablation. PDA/GNS@aPD-L1 NPs were prepared by encapsulating photothermal nanoparticles (polydopamine-modified gold nanostar, PDA-GNS) with cell membrane isolated from anti-PD-L1 single-chain variable fragment (scFv) over-expressing cells. In ad-dition to disrupting PD-1/PD-L1 immunosuppressive signals, the anti-PD-L1 scFv on the membrane of PDA/GNS@aPD-L1 NPs was conducive to the accumulation of PDA-GNS at tumor sites. Importantly, the tu-mor photothermal ablation induced by PDA-GNS could reverse the immunosuppressive tumor microenvi-ronment, thereby further improving the efficiency of PD-1/PD-L1 blockade therapy. In this study, the syn-thetized PDA/GNS@aPD-L1 NPs exhibited good biocompatibility, efficient photothermal conversion ability, and enhanced tumor-targeting ability. In vivo studies revealed that a PDA/GNS@aPD-L1 NP-based thera-peutic strategy significantly inhibited tumor growth, and prolonged overall survival by further promot-ing the maturation of dendritic cells (DCs), increasing the infiltration of CD8 + T cells, and decreasing the number of immunosuppressive cells (such as regulatory T cells and myeloid-derived suppressive cells). Collectively, the developed PDA/GNS@aPD-L1 NP-based therapeutic strategy combines PD-1/PD-L1 block-ade with photothermal ablation, which could remodel the tumor microenvironment for effective clinical colorectal cancer therapy.Statement of significance Immunosuppressive tumor microenvironment is the main challenge facing programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) blockade therapy. By encapsulating photothermal nanopar-ticles (polydopamine-modified gold nanostar, PDA-GNS) with cell membrane over-expressing anti-PD -L1 single-chain variable fragment, we constructed anti-PD-L1 functionalized biomimetic nanoparticles (PDA/GNS@aPD-L1 NPs). By specific binding to the PD-L1 present on tumor cells, PDA/GNS@aPD-L1 NPs could disrupt PD-1/PD-L1 immunosuppression signaling, and effectively deliver PDA-GNS targeting to tu-mor sites. Additionally, PDA-GNS-mediated local photothermal ablation of tumors promoted the release of tumor-associated antigens and thus activated anti-tumor immune responses. Meanwhile, hyperthermia facilitates immune cell infiltration by increasing tumor vascular permeability. Therefore, PDA/GNS@aPD-L1 NPs could sensitize tumors to PD-1/PD-L1 blockade therapy by remodeling the immunosuppressive tumor microenvironment, which provides a new strategy for tumor treatment.(c) 2022 The Authors. Published by Elsevier Ltd on behalf of Acta Materialia Inc. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

A PD1 targeted nano-delivery system based on epigenetic alterations of T cell responses in the treatment of gastric cancer

Nanoparticle-Delivered Transforming Growth Factor-β1 siRNA Induces PD-1 against Gastric Cancer by Transforming the Phenotype of the Tumor Immune Microenvironment

PD-1/PD-L1 Pathway and Angiogenesis Dual Recognizable Nanoparticles for Enhancing Chemotherapy of Malignant Cancer

Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement

Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer

PD‐1 Blockade Cellular Vesicles for Cancer Immunotherapy

A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody

A DNA nanorobot targeted release aTIGIT improves the immunosuppressive state and synergizes the anti-tumor effect of aPD-1

A phenolic based tumor-permeated nano-framework for immunogenic cell death induction combined with PD-L1 immune checkpoint blockade

In situ vaccination and gene-mediated PD-L1 blockade for enhanced tumor immunotherapy

Engineered Nanogels Simultaneously Implement HDAC Inhibition and Chemotherapy to Boost Antitumor Immunity Via Pyroptosis

TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer

Genetically Engineered PD-1 Displaying Nanovesicles for Synergistic Checkpoint Blockades and Chemo-Metabolic Therapy Against Non-Small Cell Lung Cancer

Amplified cancer immunotherapy of PD-L1 blockade by sequential tumor microenvironment reshaping and DC maturation

A Nanodrug Simultaneously Inhibits Pancreatic Stellate Cell Activation and Regulatory T Cell Infiltration to Promote the Immunotherapy of Pancreatic Cancer.

Functionalized Biomimetic Nanoparticles Combining Programmed Death-1/Programmed Death-Ligand 1 Blockade with Photothermal Ablation for Enhanced Colorectal Cancer Immunotherapy.

Genetically engineered cellular nanoparticles loaded with curcuminoids for cancer immunotherapy

An innovative nanoformulation utilizing tumor microenvironment-responsive PEG-polyglutamic coating and dynamic charge adjustment for specific targeting of ER stress inducer, microRNA, and immunoadjuvant in pancreatic cancer: In vitro investigations

Multistage Cooperative Nanodrug Combined with PD-L1 for Enhancing Antitumor Chemoimmunotherapy

A DNA Hypomethylating Drug Alters the Tumor Microenvironment and Improves the Effectiveness of Immune Checkpoint Inhibitors in a Mouse Model of Pancreatic Cancer

Immune Checkpoint Reprogramming Via Sequential Nucleic Acid Delivery Strategy Optimizes Systemic Immune Responses for Gastrointestinal Cancer Immunotherapy